Regeneron Pharmaceuticals First Quarter 2025 Earnings: Revenues Disappoint

April 30, 2025

Simply Wall St

Regeneron Pharmaceuticals (NASDAQ:REGN) First Quarter 2025 Results

Key Financial Results

Revenue: US$3.03b (down 3.7% from 1Q 2024).
Net income: US$808.7m (up 12% from 1Q 2024).
Profit margin: 27% (up from 23% in 1Q 2024). The increase in margin was driven by lower expenses.
EPS: US$7.58 (up from US$6.70 in 1Q 2024).

We check all companies for important risks. See what we found for Regeneron Pharmaceuticals in our free report.

earnings-and-revenue-growth — NasdaqGS:REGN Earnings and Revenue Growth April 30th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Regeneron Pharmaceuticals Revenues Disappoint

Revenue missed analyst estimates by 6.5%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 2.8% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Regeneron Pharmaceuticals' balance sheet and an in-depth analysis of the company's financial position.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.